Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients With Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Summary

The purpose of this phase I trial is to assess the recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in patients with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies, including pancreatic cancer.

General Information

NCT#: NCT04145297
Study ID: HCI127114
Trial Phase: Phase I

Trial Sponsor: University of Utah, BioMed Valley Discoveries
Therapies Used in This Trial: Hydroxychloroquine, Ulixertinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search